SCHEMBL20483969

SCHEMBL20483969

Cc1nc(N)ccc1CN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 1/20 0.47
EGLN1 Q9GZT9 1/20 0.47
FGFR1 P11362 1/20 0.45
TLR8 Q9NR97 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
TBK1 Q9UHD2 1/20 0.43
MAP4K4 O95819 1/20 0.43
TERT O14746 1/20 0.42
PIK3CD O00329 2/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.42
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
IDO2 Q6ZQW0 1/20 0.41
MAPT P10636 1/20 0.41
MPI P34949 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15093956 0.86 VEGFA (0.47) VEGFAEGLN1TLR8CHRM2CHRM4
SCHEMBL15252410 0.84 KDM4E (0.47) KDM4EMAPTGPR119
SCHEMBL15094076 0.80 ATM (0.45) VEGFAEGLN1CHRM2CHRM4CHRM1
SCHEMBL30418929 0.80 MAP4K4 (0.51) MAP4K4ALDH1A1POLBMAPTKMT2A
SCHEMBL21698657 0.80 MAP4K4 (0.51) MAP4K4ALDH1A1POLBMAPTKMT2A
SCHEMBL465791 0.80 CHRM2 (0.47) VEGFAEGLN1CHRM2CHRM4CHRM1
SCHEMBL4291723 0.80 NR1H2 (0.50) VEGFAEGLN1FGFR1TLR8CHRM2
SCHEMBL20150071 0.80 MGLL (0.48) VEGFAEGLN1FGFR1CHRM2CHRM4
SCHEMBL465696 0.79 TBK1 (0.51) TLR8CHRM2CHRM4CHRM1CHRM3
SCHEMBL18291473 0.78 CHRM2 (0.46) VEGFAEGLN1CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10696678-B2 Kinase inhibitor, and preparing method and pharmaceutical use thereof GAN & LEE PHARMACEUTICALS (CN) 2020-06-30 US disclosed
US-20180305363-A1 KINASE INHIBITOR, AND PREPARING METHOD AND PHARMACEUTICAL USE THEREOF GAN&LEE PHARMACEUTICALS (CN) 2018-10-25 US disclosed
EP-3369734-A1 KINASE INHIBITOR, AND PREPARING METHOD AND PHARMACEUTICAL USE THEREOF Gan & Lee Pharmaceuticals (CN) 2018-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696678-B2 Kinase inhibitor, and preparing method and pharmaceutical use thereof CDK1, MAP3K1, CSNK1A1 VEGFA 3785/4885EGLN1 4838/4885FGFR1 138/4885
US-20180305363-A1 KINASE INHIBITOR, AND PREPARING METHOD AND PHARMACEUTICAL USE THEREOF CDK1, MAP3K1, CSNK1A1 VEGFA 3785/4885EGLN1 4838/4885FGFR1 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.